Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Significant Decrease in Short Interest

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 68,800 shares, a decline of 64.1% from the February 28th total of 191,900 shares. Based on an average trading volume of 1,220,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 3.6% of the shares of the stock are short sold.

Vincerx Pharma Trading Down 4.9 %

Shares of NASDAQ VINC opened at $0.54 on Friday. The firm has a 50-day moving average of $1.23 and a two-hundred day moving average of $5.23. The company has a market capitalization of $1.21 million, a price-to-earnings ratio of -0.03 and a beta of 1.43. Vincerx Pharma has a twelve month low of $0.49 and a twelve month high of $136.80.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.